Overview

Allopregnanolone is arguably the most potent endogenous neurosteroid in the human body. It is a metabolite of progesterone and acts as a powerful positive allosteric modulator of GABAA receptors -- the same target as benzodiazepines, but through a different binding site.

In 2019, allopregnanolone was FDA-approved as Brexanolone (Zulresso) for treatment of postpartum depression, validating decades of neurosteroid research. This makes it one of the few pheromone-adjacent molecules with direct FDA validation of its mechanism.

In the pheromone community, allopregnanolone is valued for its potent anxiolytic self-effects when stacked with pheromones, particularly for managing social anxiety during high-stakes interactions. Limited community testing data is available specifically for allopregnanolone as a standalone pheromone, but its neurosteroid effects are well-documented.

Chemistry

Allopregnanolone is a 5a-reduced, 3a-hydroxylated pregnane:

  • C21 pregnane skeleton
  • 5a-reduced (saturated A/B ring junction)
  • 3a-hydroxyl group (critical for GABAA activity)
  • 20-ketone on side chain

The 3a-OH stereochemistry is essential -- the 3b isomer (epiallopregnanolone/isopregnanolone, CAS 516-55-2) has opposite effects, actually antagonizing GABAA neurosteroid modulation.

Mechanism of Action

GABAA Positive Allosteric Modulation

Allopregnanolone binds to a specific site on GABAA receptors:

  • Distinct from benzodiazepine site
  • Distinct from barbiturate site
  • Prolongs chloride channel opening
  • Enhances inhibitory signaling

Receptor Selectivity

  • High efficacy at delta-subunit containing receptors (extrasynaptic)
  • Also modulates synaptic receptors (gamma-subunit)
  • Delta-containing receptors are particularly important for tonic inhibition
  • This explains the profound calming effects

Comparison to Other GABAergics

Compound Binding Site Risk Profile
Benzodiazepines BZD site Tolerance, dependence
Barbiturates Barbiturate site Narrow therapeutic window
Allopregnanolone Neurosteroid site Low tolerance potential
Alcohol Multiple sites Addiction, toxicity

Neurosteroids appear to have a better safety profile than other GABA modulators.

Effects

Anxiolytic Effects

  • Rapid anxiety reduction
  • Profound calming without sedation (at lower doses)
  • Reduced hypervigilance
  • Decreased stress response

Mood Effects

  • Antidepressant activity (FDA-approved indication)
  • Mood stabilization
  • Reduced irritability
  • Emotional equilibrium

Cognitive Effects

  • Reduced cognitive interference from anxiety
  • Enhanced social comfort
  • May impair memory at high doses (like all GABAergics)

Physical Effects

  • Muscle relaxation
  • Anticonvulsant
  • Analgesic (pain-reducing)
  • Sedative at higher doses

Pheromone Community Use

  • Used by PheromoneXS in pheromone formulations
  • Valued for potent anti-anxiety self-effects when stacked with pheromones
  • PheroTruth community noted its relationship to pregnenolone and DHEA as evidence of pheromone relevance
  • Too large and polar to be volatile — effects are neurosteroid-mediated, not airborne signaling
  • The calm confidence it produces can alter social dynamics indirectly

Dosage Guidelines

Level Amount
Light 5-10 mg
Moderate 15-25 mg
Strong 30-50 mg

Notes:

  • Start LOW -- effects are potent
  • Duration: 3-6 hours
  • Can cause sedation at higher doses
  • Best for high-anxiety situations

Biosynthesis

Allopregnanolone is synthesized from progesterone:

Progesterone
    | (5a-reductase)
5a-dihydroprogesterone
    | (3a-HSD)
Allopregnanolone

Synthesis occurs in:

  • Brain (neurons and glia)
  • Ovaries
  • Adrenal glands
  • Placenta (high during pregnancy)

Medical Applications

FDA-Approved: Postpartum Depression

Brexanolone (IV allopregnanolone) was approved in 2019 for PPD:

  • Single 60-hour infusion
  • Rapid onset (within hours)
  • Sustained effects (30+ days)
  • Represents breakthrough in depression treatment

Research Areas

  • General depression
  • PTSD
  • Anxiety disorders
  • Traumatic brain injury
  • Epilepsy

Stacking Considerations

Pairs well with:

  • Androstenone (counters the intimidation/anxiety of high androstenone doses)
  • Pregnenolone (balances the GABA antagonism of pregnenolone)
  • Stimulating compounds (balances them out)

Caution with:

  • Other sedating neurosteroids (additive sedation)
  • Alcohol (additive GABA effects)
  • High doses of androsterone or androstenol (which are already GABAergic)

Community Consensus

Rating: 6/10

A potent neurosteroid with well-validated anxiolytic and mood effects (FDA-approved as Brexanolone for postpartum depression). Used by PheromoneXS in formulations and valued in the pheromone community for its self-effects — particularly calm confidence and social anxiety reduction. However, it is not a pheromone in the traditional sense (not volatile, not detected externally). The rating reflects its genuine utility as a pheromone stack component while acknowledging limited community testing data as a standalone pheromone molecule.

Strengths:

  • Most potent natural GABAA modulator
  • FDA-validated mechanism (Brexanolone/Zulresso)
  • Used by PheromoneXS in pheromone formulations
  • Rapid onset anxiolytic effects
  • Lower tolerance potential than benzodiazepines
  • Well-characterized pharmacology

Limitations:

  • Not a traditional airborne pheromone — effects are internal neurosteroid activity
  • Can be sedating at higher doses
  • May impair memory at high doses
  • Requires careful dosing
  • Limited pheromone community testing data as a standalone molecule

Sources